Serum VEGF increases in diabetic polyneuropathy, particularly in the neurologically active symptomatic stage

Diabetic Medicine

Volumn 26, Issue 3, 2009, Pages 247-252

  Deguchi, T ^a,c   Hashiguchi, T ^d   Horinouchi, S ^b   Uto, T ^b   Oku, H ^b   Kimura, K ^c   Makisumi, K ^e   Arimura, K ^c  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY HOSPITAL   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d KAGOSHIMA UNIVERSITY   (Japan)

^e Southern Region Hospital   (Japan)

Author keywords

Diabetes; Neuropathy; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL FEATURE; CONTROL GROUP; CONTROLLED STUDY; DIABETIC NEUROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE;

AGED; ANALYSIS OF VARIANCE; DIABETIC NEUROPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 62449309057     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02680.x     Document Type: Article

References (30)

1. Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res 1994 28 : 1176 1179.
2. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992 359 : 843 845.
3. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995 92 : 10457 10461.
4. Williams B, Gallacher B, Patel H, Orme C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997 46 : 1497 1503.
5. Natarajan R, Bai W, Lanting L, Gonzales N, Nadler J. Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells. Am J Physiol 1997 273 : 2224 2231.
6. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 1998 101 : 1219 1224.
7. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994 331 : 1480 1487.
8. Obrosova IG, Minchenko AG, Marinescu V, Fathallah L, Kennedy A, Stockert CM et al. Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 2001 44 : 1102 1110.
9. Kim NH, Kim KB, Kim DL, Kim SG, Choi KM, Baik SH et al. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus. Diabet Med 2004 21 : 545 551.
10. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002 51 : 3090 3094.
11. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001 12 : 993 1000.
12. Lip PL, Chatterjee S, Caine GJ, Hope-Ross M, Gibson J, Blann AD et al. Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. Br J Ophthalmol 2004 88 : 1543 1546.
13. Kim NH, Oh JH, Seo JA, Lee KW, Kim SG, Choi KM et al. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int 2005 67 : 167 177.
14. Mathews MK, Merges C, McLeod DS, Lutty GA. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci 1997 38 : 2729 2741.
15. Kanesaki Y, Suzuki D, Uehara G, Toyoda M, Katoh T, Sakai H et al. Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis 2005 45 : 288 294.
16. Kakizawa H, Itoh M, Itoh Y, Imamura S, Ishiwata Y, Matsumoto T et al. The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism 2004 53 : 550 555.
17. Quattrini C, Jeziorska M, Boulton AJ, Malik RA. Reduced vascular endothelial growth factor expression and intra-epidermal nerve fiber loss in human diabetic neuropathy. Diabetes Care 2008 31 : 140 145.
18. Dyck PJ. Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 1988 11 : 21 32.
19. Yasuda H, Sanada M, Kitada K, Terashima T, Kim H, Sakaue Y et al. Rationale and usefulness of newly devised abbreviated diagnostic criteria and staging for diabetic polyneuropathy. Diabetes Res Clin Pract 2007 77 : 178 183.
20. Hashiguchi T, Arimura K, Matsumuro K, Otsuka R, Watanabe O, Jonosono M et al. Highly concentrated vascular endothelial growth factor in platelets in Crow-Fukase syndrome. Muscle Nerve 2000 23 : 1051 1056.
21. Kimura K, Hashiguchi T, Deguchi T, Horinouchi T, Uto T, Oku H et al. Serum VEGF-As a prognostic factor of atherosclerosis. Atherosclerosis 2007 194 : 182 188.
22. Dyck PJ, Larson TS, O'Brien PC, Velosa JA. Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts. Nerve growth factor study group. Diabetes Care 2000 23 : 510 517.
23. Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes Metab Rev 1995 11 : 193 225.
24. Schratzberger P, Walter DH, Rittig K, Bahlmann FH, Pola R, Curry C et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001 107 : 1083 1092.
25. Chattopadhyay M, Krisky D, Wolfe D, Glorioso JC, Mata M, Fink DJ. HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther 2005 12 : 1377 1384.
26. Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. BioEssays 2004 26 : 943 954.
27. Price SA, Dent C, Duran-Jimenez B, Liang Y, Zhang L, Rebar EJ et al. Gene transfer of an engineered transcription factor promoting expression of VEGF-A protects against experimental diabetic neuropathy. Diabetes 2006 55 : 1847 1854.
28. Burgos R, Simo R, Audi L, Mateo C, Mesa J, Garcia-Ramirez M et al. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia 1997 40 : 1107 1109.
29. Duh E, Aiello LP. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 1999 48 : 1899 1906.
30. Tsutsumi Y, Losordo DW. Double face of VEGF. Circulation 2005 112 : 1248 1250.